New research by Bocconi University's Paola Cillo and Gaia Rubera with Texas A&M's David Griffith asserts that the reaction of large individual investors to innovation is an important component of stock returns, their reaction to innovation depends on their national culture, and there is a way to segment large individual investors and pitch innovation to them accordingly.
New research by Bocconi University's Mariano Max Croce and colleagues finds that public debt is bad for growth also because it hinders innovative firms' investment. 'By affecting their cost of capital, movements in government debt impact firms' investment and, critically, innovation decisions,' Professor Croce says. The net result is a GDP growth drop in four to five years, when the lack of innovation starts to affect the national economy.
Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways leading to pharmaceutically complex molecules, researchers in Poland and South Korea have unveiled computerized methods to suggest only synthetic strategies that bypass patent-protected aspects of essential drugs. Their work appears Jan. 17, 2019, in the journal Chem.
Plant breeders at the University of Göttingen and Agrecol have launched a joint initiative to protect seeds as common property. Agrecol developed an 'Open Source Seed Licence,' which legally protects seeds as commons (i.e., a natural resource accessible to all members of society) and thus protects them from patenting and similar issues such as 'plant variety protection.' The results were published in the journal PLOS Biology.
New research publishing Nov. 20 in the open-access journal PLOS Biology from Joshua Wallach, Kevin Boyack, and John Ioannidis suggests that progress has been made in key areas of research transparency and reproducibility. The authors randomly sampled biomedical journal articles published between 2015 and 2017 and assessed measures of reproducibility and transparency.
Confusion and ambiguity in how US patients and researchers perceive genetic privacy is uncovered by a study published Oct. 31, 2018 in the open-access journal PLOS ONE by Ellen W. Clayton from Vanderbilt University, USA, and colleagues.
New study finds that between 1999 and 2014, only 25 new antibiotics entered the global market. The majority of antibiotics released in this time period originated from Japanese or US companies and were launched in Japan or the US. Of the 25 antibiotics, 18 treat community-acquired respiratory infections, 14 treat skin infections, and 12 treat urinary infections. Half treat infections caused by resistant bacteria, but none targeted Gram-negative bacteria, which cause most untreatable infections.
Research carried out at the University of York has suggested that more work is needed to show that digital forensic methods are robust enough to stand-up to interrogation in a court of law.
The development, manufacture and sale of pharmaceutical drugs in the United States is a complex landscape of intellectual property and federal regulation. The status quo of the US pharmaceutical market may soon be turned on its head. That's due in part to a growing community of do-it-yourself 'biohackers' who are disrupting business-as-usual for pharmaceutical discovery, development and distribution.
Methodology developed by Brazilian scientists uses big data tools, has been validated in an analysis of studies on hemophilia, and can also be used to search for partnerships and technology transfer opportunities.